Breath Right guidance
This article was originally published in The Tan Sheet
Executive Summary
Abrupt end of cold/flu season in U.S. prompts firm to lower projections for fourth quarter results. Sales now expected in the $21 mil. to $23 mil. range, and the firm projects a loss of $.07 to $.02 per share. The marketer of Breath Right nasal strips and Vapor Shot personal vaporizer previously forecast sales in the $23.5 mil. to $25.5 mil. range and earnings of between breakeven and $.03 per share...